Statistical analysis and insight into activity and trends in M&A and capital markets.

Close up of people looking at some papers

Recent Investment Banking Insights

Waiting for the Dam to Burst in Secondaries

Much of what can be said for the overall M&A market heading into 2024 can be said for secondaries—activity still hasn’t fully recovered, there’s a lot of capital on the sidelines, and global turmoil keeps getting in the way. In this quarterly update, we look back at 2023 and forward to 2024, with close looks at GP-led secondaries and the evolution of underserved areas.

Read more

Enhancing Results With a Buy-Side Debt Advisor

Buy-side financing has become increasingly complex, with direct lending dominating middle-market leveraged buyouts and acquisitions. New lenders and strategies have emerged, while investment committees have become fickle and are frequently deterred by complex credit stories.

Watch the video

The Quarterly Rx: Q3 2023 U.S. Biopharma Recap

Biopharma indices finished Q3 near recent lows, amidst resurfacing macro concerns, including a more hawkish Federal Reserve, equity outflows, and the (now averted) shutdown of the federal government in the United States.

Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit